Second chance: experimental access to CAR T-Cell therapy for patients whose treatment batches Don't meet commercial standards

NCT ID NCT05776134

AVAILABLE Disease control Sponsor: Kite, A Gilead Company Source: ClinicalTrials.gov ↗

First seen Apr 26, 2026 · Last updated Jun 23, 2026 · Updated 10 times

Summary

This expanded access study provides brexacabtagene autoleucel (Tecartus) to patients with mantle cell lymphoma or acute lymphoblastic leukemia whose commercially manufactured batch did not meet release specifications but still meets internal clinical trial criteria. Eligible patients receive a single infusion of their own genetically modified immune cells. The goal is to offer a treatment option when the commercial product is unavailable.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Avera Cancer Institute
AVAILABLE

Sioux Falls, South Dakota, 57105, United States
Banner MD Anderson Cancer Center
AVAILABLE

Gilbert, Arizona, 85234, United States
Baylor University Medical Center
AVAILABLE

Dallas, Texas, 75246, United States
Beth Israel Deaconess Medical Center
AVAILABLE

Boston, Massachusetts, 02215, United States
City of Hope
AVAILABLE

Duarte, California, 91010, United States
Cleveland Clinic
AVAILABLE

Cleveland, Ohio, 44195, United States
Colorado Blood Cancer Institute
AVAILABLE

Denver, Colorado, 80218, United States
Dana Farber Cancer Institute - Chestnut Hill
AVAILABLE

Boston, Massachusetts, 02215, United States
Fox Chase Cancer Center
AVAILABLE

Philadelphia, Pennsylvania, 19111, United States
Fred Hutchinson Cancer Center
AVAILABLE

Seattle, Washington, 98109, United States
Hospital of the University of Pennsylvania
AVAILABLE

Philadelphia, Pennsylvania, 19104, United States
Houston Methodist Hospital
AVAILABLE

Houston, Texas, 77030, United States
Huntsman Cancer Institute, University of Utah
AVAILABLE

Salt Lake City, Utah, 84112, United States
Icahn School of Medicine at Mount Sinai
AVAILABLE

New York, New York, 10029, United States
John Theurer Cancer Center at Hackensack University Medical Center
AVAILABLE

Hackensack, New Jersey, 07601, United States
MD Anderson Cancer Center
AVAILABLE

Houston, Texas, 77030, United States
Massachusetts General Hospital
AVAILABLE

Boston, Massachusetts, 02114, United States
Mayo Clinic
AVAILABLE

Rochester, Minnesota, 55902, United States
Mayo Clinic Jacksonville
AVAILABLE

Jacksonville, Florida, 32224, United States
Medical College of Wisconsin
AVAILABLE

Milwaukee, Wisconsin, 53227, United States
Methodist Healthcare System of San Antonio dba Methodist Hospital
AVAILABLE

San Antonio, Texas, 782229, United States
Montefiore Medical Center (MMC)
AVAILABLE

The Bronx, New York, 10467, United States
Northside Hospital
AVAILABLE

Atlanta, Georgia, 30342, United States
Northwestern Memorial Hospital
AVAILABLE

Chicago, Illinois, 60611, United States
Oregon Health & Science University
AVAILABLE

Portland, Oregon, 97239, United States
Roswell Park Cancer Institute
AVAILABLE

Buffalo, New York, 14263, United States
Sarah Canon Research Institute
AVAILABLE

Nashville, Tennessee, 37203, United States
St. Luke's Cancer Institute
AVAILABLE

Boise, Idaho, 83712, United States
Tennessee Oncology
AVAILABLE

Nashville, Tennessee, 37203, United States
The Ohio State University
AVAILABLE

Columbus, Ohio, 43201, United States
The University of Kansas Medical Center
AVAILABLE

Westwood, Kansas, 66205, United States
UNC Hospitals, The University of North Carolina at Chapel Hill
AVAILABLE

Chapel Hill, North Carolina, 27514, United States
UPMC Hillman Cancer Center
AVAILABLE

Pittsburgh, Pennsylvania, 15232, United States
University of Alabama at Birmingham
AVAILABLE

Birmingham, Alabama, 35234, United States
University of Maryland Cancer Center
AVAILABLE

Baltimore, Maryland, 21201, United States
University of Michigan
AVAILABLE

Ann Arbor, Michigan, 48109, United States
University of Nebraska Medical Center
AVAILABLE

Omaha, Nebraska, 68198, United States
University of Rochester Medical Center
AVAILABLE

Rochester, New York, 14642, United States
Vanderbilt-Ingrim Cancer Center
AVAILABLE

Nashville, Tennessee, 37232, United States
Virginia Commonwealth University
AVAILABLE

Richmond, Virginia, 23298, United States
Washington University School of Medicine- Siteman Cancer Center
AVAILABLE

St Louis, Missouri, 63110, United States
Weill Cornell Medicine - NewYork-Presbyterian Hospital
AVAILABLE

New York, New York, 10021, United States
West Virginia University
AVAILABLE

Morgantown, West Virginia, 26506, United States
Winship Cancer Institute
AVAILABLE

Atlanta, Georgia, 30322, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Brexucabtagene autoleucel (Tecartus), a CAR T-cell therapy made from the patient's own immune cells

What this could lead to

If successful, this could offer a treatment option for patients who otherwise have no access to their prescribed CAR T-cell therapy due to manufacturing issues.

What could go wrong

This is an expanded access program, not a formal trial, so data on safety and effectiveness is limited. The therapy itself carries risks like severe immune reactions and neurological side effects.

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia mantle cell lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA MANTLE CELL LYMPHOMA